Alcon Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Endicott
- Full Time Employees
- 25,000
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Chemin de Blandonnet 8 Geneva GE Switzerland 1214
- IPO Date
- Apr 9, 2019
- CIK
- 0001167379
- Website
- alcon.com
- Similar Companies
- Business
- Alcon Inc. (ALC) develops, manufactures and markets innovative eye care products worldwide, operating through two primary segments: Surgical, which provides a comprehensive portfolio of technologies and devices for cataract, vitreoretinal and refractive surgery including advanced technology intraocular lenses such as PanOptix and Vivity to treat cataracts, presbyopia and astigmatism, phacoemulsification systems like Centurion, femtosecond laser systems, advanced viscoelastics, surgical packs and disposable products; and Vision Care, which offers daily disposable, reusable and color-enhancing contact lenses under brands including Dailies Total1 and Air Optix, lens care solutions, and ocular health products for dry eye, allergies, redness relief and vitamins. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and its main operational base in Fort Worth where it employs around 4,500 people; it spun off from Novartis in April 2019 as a standalone public entity and conducts operations in 60 countries while serving patients in over 140 countries with products sold in more than 180 nations, including subsidiaries such as Aerie Pharmaceuticals for glaucoma therapies and WaveLight for laser eye surgery systems. Recent strategic expansions include agreements in 2025 to acquire LENSAR Inc. for approximately $356 million to integrate the ALLY Robotic Cataract Laser Treatment System and enhance femtosecond laser-assisted cataract surgery capabilities, STAAR Surgical Company for around $1.5 billion to add EVO implantable collamer lenses for myopia and astigmatism correction as a complement to laser vision procedures, a majority interest in Aurion Biotech for advanced cell therapies targeting eye diseases, and LumiThera Inc. for its photobiomodulation device treating early and intermediate dry age-related macular degeneration, with all transactions slated to close in mid-to-late 2025.
Company News
Alcon: A Re-Rating In Eyesight
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Alcon Prices EUR 500 Million Senior Notes Offering
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy
Bill Ackman Just Disclosed 6 New Positions, and 4 of Them Are Financial Stocks. Here's What He's Betting On.
Why Netflix Stock Popped Today
Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
Alcon Stock Jumps 4% as Tariff Relief Lifts Profit Target
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth
Aecom, Alcon And 3 Stocks To Watch Heading Into Monday
Alcon (ALC) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Here's Why Alcon (ALC) is a Strong Value Stock
Do Options Traders Know Something About Alcon Stock We Don't?
Algoma Central Corporation to Issue Second Quarter Financial Results on August 7, 2026
Alcon (ALC) is a Top-Ranked Momentum Stock: Should You Buy?